Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $21.47
Previous CloseN/A
Volume723.92K
Average Volume (3M)5.56M
Market Cap
$1.75B
Enterprise Value$615.77M
Total Cash (Recent Filing)$459.65M
Total Debt (Recent Filing)$102.59M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Nov 06, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding107,346,886
10 Day Avg. Volume8,565,961
30 Day Avg. Volume5,564,141
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue11.65
Enterprise Value/Gross Profit12.91
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$31.73Price Target Upside87.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe longer-term data from Intellia's trial shows robust and durable TTR reduction with a well-tolerated profile.
Financial PositionNTLA ended 2Q25 with $630.5M in cash, providing a strong financial position.
Market DemandIntellia has fully enrolled ~60 patients in the pivotal Phase 3 trial of lonvo-z just nine months after first dosing, indicating strong demand for the one-time gene-editing treatment.
Bears Say
Price Target AdjustmentThe price target for the stock has been slightly decreased.
Product Launch DelayThe launch of a key product has been delayed based on management commentary.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $5.90 and its highest was $21.47 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.75B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.018 by $0.038.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 107,346,886 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.018. Following the earnings report the stock price went up 0.792%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
Intellia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.73 (87.53% Upside)
$31.73 (87.53% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $873.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.42%
12-Months-Change
Fundamentals
Return on Equity
-56.95%
Trailing 12-Months
Asset Growth
-24.56%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong progress in clinical trials and financial stability with accelerated enrollment and positive interim data, balanced by the forthcoming retirement of the CMO and some reported adverse events.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$31.73
▲(87.53% Upside)
Technical Analysis
Xencor
―
Rocket Pharmaceuticals
―
Arvinas Holding Company
―
Vir Biotechnology
―
Nurix Therapeutics
―
Ownership Overview
1.75% Insiders
17.93% Mutual Funds
35.45% Other Institutional Investors
15.12% Public Companies and Individual Investors